A sensitive radioimmunoassay for vincristine and vinblastine
- PMID: 7397941
- DOI: 10.1007/BF00254016
A sensitive radioimmunoassay for vincristine and vinblastine
Abstract
A rapid, sensitive and highly reproducible radioimmunoassay (RIA) has been devised for vincristine and vinblastine. These alkaloids bind to the antiserum very tightly with an association constant (Ka) of 5 x 10(9) M-1 as determined by Scatchard analysis. The kinetic association constant of the alkaloids, as determined by the 'on' and 'off' rates at 4 degrees C, is 30-fold higher than the Scatchard analysis value. At 4 degrees C, 80% of the alkaloid is bound to the antiserum within 20 min, and the remaining 20% reaches an equilibrium within 48-72 h. In the RIA procedure the amount of the alkaloid (1-2 ng) needed to compete for 50% binding remains unchanged when the reaction mixtures are incubated for 2, 4, or 20 h. By a modification of the RIA procedure, where the antiserum is first allowed to react with the unlabeled alkaloid followed by addition of the radiolabeled alkaloid, sensitivity of the assay has been increased five- to tenfold. Other drugs, such as adriamycin, CCNU, methyl CCNU, cyclophosphamide, 5-fluorouracil, heparin, hydrocortisone, prednisone, and nitrogen mustard do not interfere with the assay. This assay can thus be used to determine vincristine or vinblastine levels in 5 x 10(-10)--10(-9) M concentrations in biological fluids.
Similar articles
-
Radioimmunoassay of vinblastine and vincristine.Br J Clin Pharmacol. 1977 Apr;4(2):169-72. doi: 10.1111/j.1365-2125.1977.tb00690.x. Br J Clin Pharmacol. 1977. PMID: 558786 Free PMC article.
-
Pharmacokinetics of vindesine and vincristine in humans.Cancer Res. 1977 Aug;37(8 Pt 1):2603-7. Cancer Res. 1977. PMID: 872088
-
The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer.Med Pediatr Oncol. 1982;10(2):115-27. doi: 10.1002/mpo.2950100202. Med Pediatr Oncol. 1982. PMID: 7070351
-
Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.Cancer Res. 1993 Aug 1;53(15):3536-40. Cancer Res. 1993. PMID: 8339259 Clinical Trial.
-
Can MOPP be replaced in the treatment of advanced Hodgkin's disease?Semin Oncol. 1990 Feb;17(1 Suppl 2):2-6. Semin Oncol. 1990. PMID: 1689509 Review.
Cited by
-
Clinical pharmacology of vinzolidine.Cancer Chemother Pharmacol. 1986;16(1):70-4. doi: 10.1007/BF00255290. Cancer Chemother Pharmacol. 1986. PMID: 3940223
-
Progress in Immunoassays of Toxic Alkaloids in Plant-Derived Medicines: A Review.Toxins (Basel). 2022 Feb 23;14(3):165. doi: 10.3390/toxins14030165. Toxins (Basel). 2022. PMID: 35324662 Free PMC article. Review.
-
Phase II trial of vincristine infusion in acute leukemia.Cancer Chemother Pharmacol. 1985;14(1):26-9. doi: 10.1007/BF00552720. Cancer Chemother Pharmacol. 1985. PMID: 3965157
-
Pharmacokinetics of vindesine bolus and infusion.Cancer Chemother Pharmacol. 1984;13(2):114-9. doi: 10.1007/BF00257126. Cancer Chemother Pharmacol. 1984. PMID: 6467494
-
Preclinical and clinical pharmacology of vinca alkaloids.Drugs. 1992;44 Suppl 4:1-16; discussion 66-9. doi: 10.2165/00003495-199200444-00002. Drugs. 1992. PMID: 1283846 Review.